GURUFOCUS.COM » STOCK LIST » Latin America » Argentina » BUE » Biogen Inc (BUE:BIIB) » Definitions » Other Gross PPE
Switch to:

Biogen (BUE:BIIB) Other Gross PPE

: ARS1,169,140 Mil (As of Mar. 2023)
View and export this data going back to 2019. Start your Free Trial

Biogen's Other Gross PPE for the quarter that ended in Mar. 2023 was ARS1,169,140 Mil.

Biogen's quarterly Other Gross PPE declined from Sep. 2022 (ARS804,368 Mil) to Dec. 2022 (ARS85,770 Mil) but then increased from Dec. 2022 (ARS85,770 Mil) to Mar. 2023 (ARS1,169,140 Mil).

Biogen's annual Other Gross PPE increased from Dec. 2020 (ARS43,774 Mil) to Dec. 2021 (ARS50,131 Mil) and increased from Dec. 2021 (ARS50,131 Mil) to Dec. 2022 (ARS85,770 Mil).


Biogen Other Gross PPE Historical Data

The historical data trend for Biogen's Other Gross PPE can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biogen Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Other Gross PPE
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3,559.35 31,470.80 43,774.30 50,131.44 85,769.74

Biogen Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Other Gross PPE Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 624,239.65 698,780.39 804,367.64 85,769.74 1,169,140.44

Biogen Other Gross PPE Calculation

GuruFocus lists Land And Improvements, Buildings And Improvements, Machinery, Furniture, Equipment, Construction In Progress and Other Gross PPE under the "Gross Property, Plant and Equipment" section.


Biogen (BUE:BIIB) Business Description

Biogen logo
Address
225 Binney Street, Cambridge, MA, USA, 02142
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021, followed by Leqembi in January 2023.

Biogen (BUE:BIIB) Headlines